Abstract
Ceftazidime, a new cephalosporin with enhanced activity against aerobic gram-negative bacilli, was compared with tobramycin and ticarcillin in a randomized clinical trial. Efficacy and safety were evaluated in 18 patients (17 males, 1 female) with gram-negative osteomyelitis. All organisms were susceptible to the treatment antibiotics(s). There were nine patients treated with tobramycin and ticarcillin for 27 to 62 days (mean, 42 days), and nine patients were treated with 4 g of ceftazidime per day for 26 to 63 days (mean, 45 days). All nine patients receiving tobramycin and ticarcillin had the osteomyelitis arrested after the initial treatment. Follow-up was for 2 to 38 months (mean, 22 months). Of nine patients receiving ceftazidime three were initial treatment failures. Follow-up was for 13 to 31 months (mean, 21 months). A patient receiving ceftazidime had a transient rise in serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase. There were three treatment failures in the ceftazidime group; no failures occurred in the group receiving the combination of ticarcillin and tobramycin. A larger series would be required to detect a significant difference between the two treatment groups.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clumeck N., Van Laethem Y., Gordts B., Jaspar N., Butzler J. P. Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms. Antimicrob Agents Chemother. 1983 Aug;24(2):176–180. doi: 10.1128/aac.24.2.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eron L. J., Goldenberg R. I., Park C. H., Poretz D. M. Ceftazidime therapy of serious bacterial infections. Antimicrob Agents Chemother. 1983 Feb;23(2):236–241. doi: 10.1128/aac.23.2.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fu K. P., Neu H. C. In vitro study of netilmicin compared with other aminoglycosides. Antimicrob Agents Chemother. 1976 Sep;10(3):526–534. doi: 10.1128/aac.10.3.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Jan;21(1):11–18. doi: 10.1128/aac.21.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Norrby R., Foord R. D., Hedlund P. Clinical and pharmacokinetic studies on cefuroxime. J Antimicrob Chemother. 1977 Jul;3(4):355–362. doi: 10.1093/jac/3.4.355. [DOI] [PubMed] [Google Scholar]
- O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reynolds A. V., Hamilton-Miller J. M., Brumfitt W. Diminished effect of gentamicin under anaerobic or hypercapnic conditions. Lancet. 1976 Feb 28;1(7957):447–449. doi: 10.1016/s0140-6736(76)91474-4. [DOI] [PubMed] [Google Scholar]
- Sheftel T. G., Cierny G., 3rd, Lefrock J. L., Mader J. T. Cefmenoxime therapy in bacterial osteomyelitis. Am J Med. 1984 Dec 21;77(6A):17–20. doi: 10.1016/s0002-9343(84)80068-6. [DOI] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Bedford K. A. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother. 1980 May;17(5):884–889. doi: 10.1128/aac.17.5.884. [DOI] [PMC free article] [PubMed] [Google Scholar]